EphB4

EphB4 Informations sur la molécule

Nom anglais	Ephrin type-B receptor 4	Nombre de médicaments commercialisés	0
Nombre de médicaments cliniques	2	Alias de la cible	Ephrin type-B receptor 4，MYK1，EPHB4，HTK，EPH Receptor B4，Tyrosine-Protein Kinase TYRO11，TYRO11，Tyrosine-Protein Kinase Receptor HTK，Soluble EPHB4 Variant 2，Soluble EPHB4 Variant 3，Ephrin Receptor EphB4，EC 2.7.10.1，HFASD，LMPHM7，CMAVM2，EC 2.7.10，EC:2.7.10.1，Soluble EPHB4 Variant 1，Receptor， EphB4，Hepatoma transmembrane kinase
Phase de R&D la plus avancée	Phase 3 Clinical

Nom anglais	Ephrin type-B receptor 4
Alias de la cible	Ephrin type-B receptor 4，MYK1，EPHB4，HTK，EPH Receptor B4，Tyrosine-Protein Kinase TYRO11，TYRO11，Tyrosine-Protein Kinase Receptor HTK，Soluble EPHB4 Variant 2，Soluble EPHB4 Variant 3，Ephrin Receptor EphB4，EC 2.7.10.1，HFASD，LMPHM7，CMAVM2，EC 2.7.10，EC:2.7.10.1，Soluble EPHB4 Variant 1，Receptor， EphB4，Hepatoma transmembrane kinase
Nombre de médicaments commercialisés	0
Nombre de médicaments cliniques	2
Phase de R&D la plus avancée	Phase 3 Clinical

EphB4 Liste de produits

Attribut
Protein (2)
Bibliothèque de produits
En ligne (2)
Espèces
Human (2)
Étiquette
His Tag (2)
Marqueur
Unconjugated (1)Biotin-labeled (1)

Numéro de produit	Espèces	Système d'expression	Description du produit	Structure protéique	Pureté	Caractéristiques	Pré-commande/Commande
EP4-H5229	Human	HEK293	Human EphB4 Protein, His Tag				Ajouter au panier
EP4-H8229	Human	HEK293	Biotinylated Human EphB4 Protein, His Tag, ultra sensitivity (primary amine labeling)				Ajouter au panier

Quantité totale2

EphB4Contexte de la molécule

Ephrin type-B receptor 4(EPHB4) is also known as HTK, MYK1 and TYRO11,is a member of Eph family. The Eph family of receptors are divided into 2 groups based on the similarity of their extracellular domain sequences and their affinities for binding ephrin-A and ephrin-B ligands. Ephrin receptors make up the largest subgroup of the receptor tyrosine kinase (RTK) family. The protein encoded by EPHB4 binds to Ephrin-B2 and plays an essential role in vascular development. EPHB4 and its ligand ephrin-B2 are specifically expressed on venous and arterial endothelial cells, respectively, and play an essential role in vascular development via bidirectional signals. The forward EPHB4 signaling inhibits cell adhesion, chemotaxis, angiogenesis and tumor growth. Incontrast, the reverse Ephrin-B2 signaling exerts the opposite effect. It has been reported that aberrant expression of EPHB4 is associated with prostate cancer and highly malignant breast cancers, accordingly, EPHB4 has potential application as a therapeutic candidate.

EphB4Alias de la molécule

EphB4,HTK,MYK1,TYRO11

Informations sur les médicaments cliniques

Nom anglais	Code de recherche	Phase de R&D	Entreprise	Indication	Essai clinique
sEphB4-HSA	Vas-01; sEphB4-HSA	Phase 3 Clinical	Vasgene	Bile Duct Neoplasms; Bone metastases; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Gallbladder Neoplasms; Leukemia, Myelogenous, Chronic; Leukemia, Myeloid, Acute; Myelodysplastic-Myeloproliferative Diseases; Pancreatic Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Sarcoma; Sarcoma, Kaposi; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Urinary Bladder Neoplasms	Details
Tesevatinib	XL-647; KD-020; KD-019; EXEL-7647	Phase 2 Clinical	Exelixis Inc	Brain metastases; Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Glioblastoma; Neoplasm Metastasis; Neoplasms; Polycystic Kidney, Autosomal Dominant; Polycystic Kidney, Autosomal Recessive	Details